Caitlyn Eren Knoebel

Recommended Articles

• Why Are Nursing Schools Rejecting Qualified Applicants?

  There is a nursing shortage in the U.S., but schools are rejecting hundreds of competent applicants. Why is this happening? Well, there are definitely a few reasons. Class size and the need to hire more teachers to manage nursing programs, and clinical programs need to be expanded. ...

• Gluten-Free Food Bank Helps Families in Need in Massachusetts

  Celiac disease is a chronic condition caused in the digestive tract, it has an immunological origin characterized by a permanent intolerance to a protein called gluten which is present in cereals (wheat, oats, barley or rye). When the patient ingests foods containing gluten, the lining of the small...

• Young Ballerina with Muscular Dystrophy Has Her Dream Come True

  Dreams do come true, which has been the case for Jessica Kennedy. When she was just 18 months old, Jessica was diagnosed with muscular dystrophy. Now seven, she is bound to a wheelchair with limited mobility, but this little girl is still full of dreams.One of them is to become a ballerina and be...

• 8 Helpful Tips to Protect Tooth Enamel

  Enamel, the hard coating on the surface of the teeth, is designed to last long even though wear and tear occurs throughout one's lifetime. “This is the hardest substance in the body," says Leslie Seldin, DDS, a spokesperson for the American Dental Association. There are a number of ways by which...

• What is a Glycemic Index Diet?

  The low glycemic diet, or the GI diet, as it is popularly known as, is a tool commonly used in weight loss programs. Many diet plans are based on this tool, including South Beach, Nutrisystem, The Zone, Sugar Busters, Glucose Revolution, and Ending the Food Fight. Glycemic index (GI) was...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...